Lifecore Biomedical, Inc. LFCR
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -21.76%
- 1 year
- -9.86%
- Open
- 6.48
- Prev close
- 6.52
- Mkt cap
- 242.60M
- Vol
- 1.02M
- Avg vol
- 357.15K
- EPS
- -1.27
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 6.32
- High
- 6.50
- Forward P/E
- -9.90
- Beta
- 0.94
- Short ratio
- 11.20
- Inst. own
- 69.84%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Jan 2, 2025
- 50-d avg
- 6.51
- 200-d avg
- 5.84
- 1y target
- 8.00
News
2 days ago globenewswire.com
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: ADT Inc. (NYSE – ADT), RXO Inc. (NYSE – RXO), PTC Inc. (Nasdaq – PTC), Lifecore Biomedical, Inc. (Nasdaq – LFCR)
BALA CYNWYD, Pa., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky…
3 weeks ago benzinga.com
Lifecore Biomedical Q2 2026 Earnings Call Transcript
Lifecore Biomedical (NASDAQ:LFCR) held its second-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For…
3 weeks ago globenewswire.com
Lifecore Biomedical to Participate at Upcoming Industry Conferences
CHASKA, Minn., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”),…
3 weeks ago gurufocus.com
Are RXO, PTC, LFCR, WAFD Obtaining Fair Deals for their Shareholders?
Are RXO, PTC, LFCR, WAFD Obtaining Fair Deals for their Shareholders?PR NewswireNEW YORK, Oct. 5, 2026Insiders may stand to receive substantial financial benefi
3 weeks ago globenewswire.com
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RXO Inc. (NYSE – RXO), PTC Inc. (Nasdaq – PTC), Lifecore Biomedical, Inc. (Nasdaq – LFCR), WaFd, Inc. (Nasdaq – WAFD)
BALA CYNWYD, Pa., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky…
4 weeks ago gurufocus.com
EQUITY ALERT - The M&A Class Action Firm Launches Inquiry -- FWAC, MGLD, LFCR, and MG
EQUITY ALERT - The M&A Class Action Firm Launches Inquiry -- FWAC, MGLD, LFCR, and MGPR NewswireNEW YORK, Oct. 3, 2026NEW YORK, Oct. 3, 2026 /PRNewswire/ --Clas
1 month ago benzinga.com
Deal Dispatch: Hormel Acquires Brakebush, Onsemi buys Synaptics for $5.7 Billion, Leslie’s Pools Bankruptcy
Major M&A deals include Valley National buys Bluevine, Roland Foods buys Savor Brands, Bloomberg completes Canoe deal.
1 month ago globenewswire.com
Halper Sadeh LLC is Investigating Whether LFCR and SSTI are Obtaining Fair Deals for their Shareholders
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
1 month ago businesswire.com
Lifecore Biomedical Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Lifecore Biomedical, Inc. - LFCR
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of…
1 month ago globenewswire.com
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Capital Bancorp, Inc. (Nasdaq – CBNK), Lifecore Biomedical, Inc. (Nasdaq – LFCR), MISTRAS Group, Inc. (NYSE – MG), Utz Brands, Inc. (NYSE – UTZ)
BALA CYNWYD, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky…
-
1 month ago benzinga.com
Wynnefield Capital Discloses About 14.3% Stake In Lifecore Biomedical, Agrees To Vote In Favor Of Its Pending Merger, Per 13D Filing
https://www.sec.gov/Archives/edgar/data/1005286/000110465926111939/xslSCHEDULE_13D_X02/primary_doc.xml
1 month ago gurufocus.com
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Lifecore Biomedical, Inc. (NASDAQ: LFCR)
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Lifecore Biomedical, Inc. (NASDAQ: LFCR)PR NewswireNEW YORK, Sept. 29, 2026NEW YORK,
1 month ago prnewswire.com
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Lifecore Biomedical, Inc. (NASDAQ: LFCR)
NEW YORK, Sept. 29, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is…
-
1 month ago benzinga.com
Barrington Research Downgrades Lifecore Biomedical to Market Perform
Barrington Research analyst Michael Petusky downgrades Lifecore Biomedical (NASDAQ:LFCR) from Outperform to Market Perform.
1 month ago newsfilecorp.com
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Lifecore Biomedical, Inc. (LFCR)
Bala Cynwyd, Pennsylvania--(Newsfile Corp. - September 29, 2026) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Lifecore…
1 month ago defenseworld.net
Lifecore agrees to acquisition with CVRs up to $160 million
What happened Lifecore Biomedical, Inc. (NASDAQ: LFCR) said on September 28, 2026, that it entered a definitive agreement to be acquired by Webster Equity Partners. Common stockholders will receive…
1 month ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Kodiak Sciences (NASDAQ:KOD) shares moved upwards by 172.3% to $88.08 during Monday's regular session. The market value of their outstanding shares is at $2.0 billion. Accuray (NASDAQ:ARAY)…
1 month ago prnewswire.com
LFCR SHAREHOLDER ALERT: ADEMI LLP INVESTIGATES WHETHER BUYOUT FAIRLY VALUES LIFECORE BIOMEDICAL, INC.
Lifecore shareholders will receive just $6.28 per share in a transaction valued at up to $663.7 million; Ademi LLP is investigating the deal price, benefits to company insiders, and restrictions on…
1 month ago gurufocus.com
LFCR Stock Alert: Halper Sadeh LLC is Investigating Whether Lifecore Biomedical, Inc. is Obtaining a Fair Price for its Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Lifecore Biomedical, Inc. (NASDAQ: LFCR) to Webster Equity Partners for $6.28 per sh
1 month ago businesswire.com
LFCR Stock Alert: Halper Sadeh LLC is Investigating Whether Lifecore Biomedical, Inc. is Obtaining a Fair Price for its Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Lifecore Biomedical, Inc. (NASDAQ: LFCR) to Webster Equity Partners for $6.28 per share in cash…
-
1 month ago benzinga.com
Lifecore Biomedical To Be Acquired By Webster Equity Partners In Up To $663.7M Transaction; Stockholders May Receive Up To $9.67 Per Common Equivalent In Combined Cash And CVR At Full Performance Milestone Payments
Lifecore Common Stockholders to Receive $6.28 per Share in Cash at Closing, Representing a 49.5% PremiumLifecore Series A Preferred Stockholders Will Receive Required "Conversion Amount" per Share in…
1 month ago globenewswire.com
Lifecore Biomedical to be Acquired by Webster Equity Partners
Lifecore Common Stockholders to Receive $6.28 per Share in Cash at Closing, Representing a 49.5% Premium Lifecore Series A Preferred Stockholders Will Receive Required “Conversion Amount” per Share…
1 month ago globenewswire.com
Lifecore Biomedical to Participate at CPHI Global Conference
CHASKA, Minn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”),…
2 months ago globenewswire.com
Lifecore Biomedical Signs Agreement for Commercial Site Transfer Supporting Global Pharmaceutical Company
-- Significant New Program Positioned to Become One of Lifecore's Largest Contracts -- -- Agreement Supports Tech Transfer and Commercial Manufacturing of Currently Marketed Drug Product -- --…
2 months ago seekingalpha.com
Lifecore Biomedical, Inc. (LFCR) Q2 2026 Earnings Call Transcript
Lifecore Biomedical, Inc. (LFCR) Q2 2026 Earnings Call Transcript
-
2 months ago benzinga.com
Lifecore Biomedical Q2 EPS $(0.19) Beats $(0.22) Estimate, Sales $34.200M Beat $32.016M Estimate
Lifecore Biomedical (NASDAQ:LFCR) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.22) by 13.64 percent. This is a 24 percent increase over losses of…
-
2 months ago benzinga.com
Lifecore Biomedical Affirms FY2026 Sales Guidance of $120.000M-$125.000M vs $122.176M Est
Lifecore Biomedical (NASDAQ:LFCR) affirms FY2026 sales outlook from $120.000 million-$125.000 million to $120.000 million-$125.000 million vs $122.176 million estimate.
2 months ago globenewswire.com
Lifecore Biomedical Reports Financial Results for the Second Quarter Ended June 30, 2026, and Provides Corporate Update
-- Reaffirms 2026 Guidance -- -- Multiple New Business Wins, Adding Impactful Programs to Pipeline -- -- Cost Reduction and Productivity Enhancements Continue to Strengthen Organization -- Conference…
-
4 months ago benzinga.com
Barrington Research Maintains Outperform on Lifecore Biomedical, Raises Price Target to $6.5
Barrington Research analyst Michael Petusky maintains Lifecore Biomedical (NASDAQ:LFCR) with a Outperform and raises the price target from $6 to $6.5.
-
5 months ago benzinga.com
Lifecore Biomedical Signs Manufacturing Services Agreement To Perform Process Development And Technical Transfer Services In Support Of Anticipated Commercial Manufacturing Upon Regulatory Approval
-- Agreement Calls for Tech Transfer in Preparation for Potential Commercial Manufacturing of Injectable Ophthalmic Product ---- Sixth Addition to Late-Stage Pipeline in Seven Months --CHASKA, Minn.,…
-
5 months ago benzinga.com
Lifecore Biomedical Q1 2026 Earnings Call Transcript
Lifecore Biomedical Q1 2026 Earnings Call Transcript
-
5 months ago benzinga.com
Lifecore Biomedical Affirms FY2026 Sales Guidance of $120.000M-$125.000M vs $122.430M Est
Lifecore Biomedical (NASDAQ:LFCR) affirms FY2026 sales outlook from $120.000 million-$125.000 million to $120.000 million-$125.000 million vs $122.430 million estimate.
-
5 months ago benzinga.com
Lifecore Biomedical Q1 EPS $(0.43) Misses $(0.24) Estimate, Sales $23.193M Miss $26.501M Estimate
Lifecore Biomedical (NASDAQ:LFCR) reported quarterly losses of $(0.43) per share which missed the analyst consensus estimate of $(0.24) by 79.17 percent. This is a 18.87 percent increase over losses…
-
6 months ago benzinga.com
Barrington Research Maintains Outperform on Lifecore Biomedical, Raises Price Target to $6
Barrington Research analyst Michael Petusky maintains Lifecore Biomedical (NASDAQ:LFCR) with a Outperform and raises the price target from $5.5 to $6.
-
7 months ago benzinga.com
Lifecore Expands Manufacturing Deal With Existing Pharma Client
Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated injectables contract development and manufacturing organization ("CDMO"), today announced that it has signed two CDMO…
-
7 months ago benzinga.com
CORRECTION: Lifecore Biomedical Q4 EPS $(0.16) Up From $(0.20) YoY, Sales $35.747M Down From $37.886M YoY
Lifecore Biomedical (NASDAQ:LFCR) reported quarterly losses of $(0.16) per share. This is a 20 percent increase over losses of $(0.20) per share from the same period last year. The company reported…
-
7 months ago benzinga.com
Barrington Research Upgrades Lifecore Biomedical to Outperform, Announces $5.5 Price Target
Barrington Research analyst Michael Petusky upgrades Lifecore Biomedical (NASDAQ:LFCR) from Market Perform to Outperform and announces $5.5 price target.
7 months ago benzinga.com
Lifecore Stock Sinks As Delayed Launches Push Growth Further Out
Lifecore stock plunges after earnings miss and weak 2026 outlook, with customer losses and delayed growth plans weighing on shares.
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
-
7 months ago benzinga.com
Lifecore Biomedical Sees FY2026 Sales $120.000M-$125.000M vs $129.846M Est
Lifecore Biomedical (NASDAQ:LFCR) sees FY2026 sales of $120.000 million-$125.000 million vs $129.846 million analyst estimate.
-
7 months ago benzinga.com
Earnings Scheduled For March 16, 2026
Earnings Scheduled For March 16, 2026
-
8 months ago benzinga.com
Lifecore Biomedical Announces Development Services Agreement To Provide Indomo With CDMO Services To Support Continued Development Of Corticosteroid Drug Candidate, DT-001
Indomo Developing Fast-Acting, At-Home Treatment for Inflammatory Acne Lesions to be Administered with the ClearPen™, its Proprietary Intradermal Self-Injection DeviceLifecore to Manufacture Drug…
-
10 months ago benzinga.com
Lifecore Biomedical Lands Major Global Pharma Deal to Make Injectable Drug in the US
Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that it has signed a CDMO master services…
-
11 months ago benzinga.com
Lifecore Biomedical Affirms FY2026 Sales Guidance of $74.000M-$76.000M vs $131.882M Est
Lifecore Biomedical (NASDAQ:LFCR) affirms FY2026 sales outlook from $74.000 million-$76.000 million to $74.000 million-$76.000 million vs $131.882 million estimate.
-
11 months ago benzinga.com
Lifecore Biomedical Q1 EPS $(0.29) Beats $(0.30) Estimate, Sales $31.109M Beat $26.471M Estimate
Lifecore Biomedical (NASDAQ:LFCR) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.30) by 4.92 percent. This is a 45.28 percent increase over losses of…
12 months ago benzinga.com
Earnings Scheduled For November 6, 2025
Earnings Scheduled For November 6, 2025
-
1 year ago benzinga.com
Lifecore Expands CDMO Business, Becomes Supplier Of Choice For Leading Injectable Drug
Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that it has signed an agreement with a leading…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session